0.8581
Schlusskurs vom Vortag:
$0.888
Offen:
$0.903
24-Stunden-Volumen:
526.52K
Relative Volume:
0.67
Marktkapitalisierung:
$113.52M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-0.2813
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+6.08%
1M Leistung:
+4.49%
6M Leistung:
-20.55%
1J Leistung:
-81.47%
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Firmenname
Rapt Therapeutics Inc
Sektor
Branche
Telefon
(650) 489-9000
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RAPT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RAPT
Rapt Therapeutics Inc
|
0.8581 | 107.01M | 3.25M | -116.80M | -98.17M | -3.05 |
![]()
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2024-11-13 | Herabstufung | Stifel | Buy → Hold |
2024-11-11 | Herabstufung | JP Morgan | Neutral → Underweight |
2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
2024-05-14 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2024-05-10 | Herabstufung | Barclays | Overweight → Equal Weight |
2024-05-10 | Herabstufung | Guggenheim | Buy → Neutral |
2024-02-22 | Herabstufung | UBS | Buy → Neutral |
2024-02-21 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2024-02-21 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-02-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2024-02-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2024-02-16 | Eingeleitet | Evercore ISI | Outperform |
2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
2023-09-14 | Eingeleitet | Berenberg | Buy |
2023-08-09 | Eingeleitet | Stifel | Buy |
2023-06-15 | Eingeleitet | Barclays | Overweight |
2023-01-04 | Eingeleitet | Guggenheim | Buy |
2022-12-01 | Eingeleitet | Goldman | Buy |
2022-09-21 | Eingeleitet | CapitalOne | Overweight |
2022-05-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2021-12-09 | Eingeleitet | JP Morgan | Overweight |
2021-08-12 | Eingeleitet | SVB Leerink | Outperform |
2021-06-21 | Eingeleitet | Piper Sandler | Overweight |
2020-06-01 | Eingeleitet | H.C. Wainwright | Buy |
2020-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-04-13 | Eingeleitet | ROTH Capital | Buy |
2019-11-25 | Eingeleitet | BMO Capital Markets | Outperform |
2019-11-25 | Eingeleitet | UBS | Buy |
2019-11-25 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Sto - GuruFocus
Comerica Bank Purchases Shares of 58,040 RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Dimensional Fund Advisors LP Sells 105,231 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World
RAPT Therapeutics Reports Improved Q1 2025 Results - TipRanks
RAPT Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Reports Third Quarter 2024 Financial Results - ADVFN
RAPT Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Has $584,000 Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
JPMorgan Chase & Co. Raises Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
There is no way RAPT Therapeutics Inc (RAPT) can keep these numbers up - Sete News
A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - uspostnews.com
Market Recap: RAPT Therapeutics Inc (RAPT)’s Positive Momentum, Closing at 0.93 - DWinneX
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Acquired by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
RAPT Therapeutics Inc (RAPT) is a good investment, but the stock may be overvalued - uspostnews.com
Stock Surge: RAPT Therapeutics Inc (RAPT) Closes at 0.79, Marking a -1.32 Increase/Decrease - DWinneX
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth? - Yahoo Finance
RAPT stock touches 52-week low at $0.78 amid sharp annual decline - Investing.com Canada
RAPT stock touches 52-week low at $0.78 amid sharp annual decline By Investing.com - Investing.com South Africa
Rapt Therapeutics appoints Jessica Savage as VP, clinical development - TipRanks
RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus
RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire
Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World
40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World
Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World
RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada
RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks
RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks
RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks
RAPT Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings - Nasdaq
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
RAPT Therapeutics, Inc. SEC 10-K Report - TradingView
Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c) - TipRanks
Can RAPT's $231M War Chest and New Food Allergy Drug Transform Its Future? - StockTitan
RAPT Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World
Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha
SG Americas Securities LLC Purchases 42,636 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):